Nili provides comprehensive legal and regulatory guidance to companies in the healthcare, life sciences, pharma, and high-tech sectors, delivering precise solutions tailored to the unique needs of each client. With over 20 years of experience, Nili specializes in assisting companies to navigate complex regulatory challenges and develop strategies that ensure both business and regulatory success.
Nili has gained extensive expertise through her pivotal roles at the Israeli Ministry of Health, where she served as the Legal Advisor to the Division of Medical Technologies and as the Commissioner for Public Complaints under the National Health Insurance Law. In these roles, she led legislative processes, developed professional guidelines, and provided comprehensive legal advice on issues such as medical technologies, the inclusion of pharmaceuticals in the healthcare basket, and their marketing. Her deep understanding of Israel’s public healthcare system, coupled with strong relationships with key stakeholders in the field, enables her to offer clients strategic guidance that delivers impactful results.
At Shibolet & Co., Nili is committed to professional and regulatory excellence, equipping her clients with the tools they need to overcome regulatory hurdles and unlock their full business potential.
Academic activity
“Pharmaceutical Law,” Lecturer, Faculty of Health Sciences, Ben-Gurion University.
Other activities
Nili is a member of the “Madonna” Association for Women in Healthcare and actively participates in initiatives to raise awareness about patient rights advocacy and reducing disparities in healthcare.
Did you know
In her role at the Ministry of Health, Nili spearheaded the design, development, and legal structuring of the key laws and regulations that have shaped Israel’s regulatory landscape for medical technologies and pharmaceuticals over the past two decades. Among her notable achievements are the legislation of pharmaceutical import reforms, the establishment of systems for monitoring adverse drug reactions, the formulation of the updated provisions of Regulation 29, the regulation of research involving biological pathogens, and the development of comprehensive regulatory frameworks for medical devices, cosmetics, blood products, and more.